Insider Selling: Vir Biotechnology, Inc. (NASDAQ:VIR) EVP Sells $22,226.09 in Stock

Vir Biotechnology, Inc. (NASDAQ:VIR) EVP Verneuil Vanina De sold 2,347 shares of the firm’s stock in a transaction that occurred on Tuesday, November 5th. The shares were sold at an average price of $9.47, for a total value of $22,226.09. Following the completion of the sale, the executive vice president now directly owns 61,370 shares in the company, valued at $581,173.90. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Verneuil Vanina De also recently made the following trade(s):

• On Friday, November 1st, Verneuil Vanina De sold 1,403 shares of Vir Biotechnology stock. The shares were sold at an average price of $7.20, for a total value of $10,101.60.

Vir Biotechnology Stock Down 3.9 %

Vir Biotechnology stock opened at $9.77 on Friday. The stock has a 50-day simple moving average of $7.83 and a 200 day simple moving average of $8.90. Vir Biotechnology, Inc. has a 12-month low of $7.12 and a 12-month high of $13.09.

Vir Biotechnology (NASDAQ:VIR) last announced its earnings results on Thursday, October 31st. The company reported ($1.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.05) by ($0.51). Vir Biotechnology had a negative return on equity of 36.71% and a negative net margin of 678.40%. The company had revenue of $2.38 million during the quarter, compared to the consensus estimate of $5.54 million. During the same period in the prior year, the firm posted ($1.22) earnings per share. The company’s revenue was down 9.8% on a year-over-year basis. Sell-side analysts anticipate that Vir Biotechnology, Inc. will post -3.86 EPS for the current year.

Analyst Ratings Changes

VIR has been the topic of several research reports. Barclays dropped their price objective on shares of Vir Biotechnology from $28.00 to $26.00 and set an “overweight” rating on the stock in a report on Monday. HC Wainwright reaffirmed a “buy” rating and set a $110.00 price objective on shares of Vir Biotechnology in a report on Monday. Finally, Needham & Company LLC reiterated a “buy” rating and set a $19.00 price objective on shares of Vir Biotechnology in a research note on Friday, November 1st. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat.com, Vir Biotechnology presently has a consensus rating of “Moderate Buy” and an average price target of $36.40.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Blue Trust Inc. boosted its stake in shares of Vir Biotechnology by 143.5% in the 3rd quarter. Blue Trust Inc. now owns 3,989 shares of the company’s stock valued at $30,000 after purchasing an additional 2,351 shares during the last quarter. Innealta Capital LLC bought a new position in Vir Biotechnology in the second quarter valued at approximately $32,000. nVerses Capital LLC acquired a new stake in Vir Biotechnology during the 3rd quarter worth $56,000. Magnetar Financial LLC bought a new stake in shares of Vir Biotechnology during the 2nd quarter valued at $95,000. Finally, Quest Partners LLC raised its position in shares of Vir Biotechnology by 142.1% during the 2nd quarter. Quest Partners LLC now owns 12,695 shares of the company’s stock valued at $113,000 after acquiring an additional 7,452 shares during the last quarter. Institutional investors and hedge funds own 65.32% of the company’s stock.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).